ClinicalTrials.gg
WithdrawnNCT03831152Updated Feb 9, 2026

Extension Study in Primary Distal Renal Tubular Acidosis

A Phase 3 interventional study of ADV7103 in Acidosis, Renal Tubular, sponsored by Advicenne Pharma. Withdrawn at 1 site in United States. Open to participants aged 4 Months to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Advicenne Pharma · Phase 3, Interventional, and Treatment

Why this study was withdrawn
No patients enrolled. Study no longer required due to completion of long term safety study in the EU.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Months to 65 Years
Sex
All
01

Study summary

Open-label study involving longitudinal assessment of the continued safety, tolerability, and efficacy of ADV7103 in maintaining targeted serum bicarbonate levels, preventing metabolic acidosis, and preventing hypokalemia in the following groups of subjects with primary dRTA:

  1. subjects who participated in Study B23CS and were adherent to the protocol;
  2. subjects ≥ 6 months of age who are living in Europe and did not participate in Study B23CS; and
  3. infants younger than 6 months of age
02

Conditions studied

  • Acidosis, Renal Tubular
03

In context

Lead sponsor

Advicenne Pharma is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who participated in Study B23CS must meet all of the following criteria to be registered into this study:

1. Female or male subjects who participated in Study B23CS and were adherent to the protocol;

Subjects who did not participate in Study B23CS must meet all of the following criteria to be registered into this study:

  1. Female or male subjects ≤ 65 years of age at time of consent with the following stipulations:

    1. Subjects ≥ 6 months of age must reside in Europe
    2. Subjects \< 6 months of age must reside in the United States, Canada, or Europe;
  2. Subjects \< 6 months of age must be able to swallow (not suck) solid food without difficulty;
  3. Subject presents with a previous diagnosis of primary dRTA;
  4. Subject ≥ 6 months of age requires ≥ 0.9 mEq/kg/day of alkali therapy to maintain serum bicarbonate levels above the LLN;
  5. Urine pH > 5.5 and serum bicarbonate > 18 mEq/L for subjects ≥ 4 years old or > 17 mEq/L for subjects \< 4 years old on alkali therapy and potassium supplementation (if indicated) on at least one occasion for each within 6 months;
  6. European subjects must be included in a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research;
  7. Subject or parent/guardian is willing and able to understand and sign and willing to comply with protocol instructions; child assent when appropriate; and

Exclusion criteria

Exclusion Criteria:

Subjects who participated in Study B23CS and meet any of the following criteria will be considered ineligible for registration into this study:

  1. Female subject who is pregnant or lactating or has plans for pregnancy during the study; or
  2. Subject requires therapy with potassium sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, trimethoprim, drospirenone and other progestins, nephrotoxic antibiotics, penicillins, tacrolimus, or medications known to delay gastric emptying or otherwise interfere with absorption of study product.

Subjects who did not participate in Study B23CS and meet any of the following criteria will be considered ineligible for registration into this study:

  1. Female subject who is pregnant or lactating or has plans for pregnancy during the study;
  2. Subject has evidence of proximal tubule dysfunction unless the subject is \< 6 months of age;
  3. Subject presents with another diagnosed condition as a potential etiology for her/his dRTA ;
  4. Subject requires therapy with potassium sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, trimethoprim, drospirenone and other progestins, nephrotoxic antibiotics, penicillins, tacrolimus, or medications known to delay gastric emptying or otherwise interfere with absorption of study product;
  5. Subject has evidence of obstructive uropathy or other findings on renal ultrasound expected to require intervention during the course of the study;
  6. Subject has any of the following laboratory abnormalities:

    1. and/or ALT > 1.5x (ULN)
    2. Serum potassium > 5.0 mEq/L or hypokalemia accompanied by clinical symptoms (eg, muscle cramps) or significant changes (eg, T wave depression, U wave elevation)
    3. Estimated (eGFR) \< 60 mL/min/1.73 m2 (according to the updated Schwartz formula for children and Chronic Kidney Disease - Epidemiology Collaboration [CKD-EPI] formula for adults)
    4. Total > ULN, except with known Gilbert's disease.
  7. Subject has been hospitalized or had outpatient surgery (other than minor skin and dRTA disease-related procedures or ear tube placement) in the past 6 months or is planning surgery in the next 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental ADV7103

    All patients receive ADV7103 at their individualized dose

    Drug: ADV7103

Interventions

06

What researchers measure

Primary outcomes

  1. The Safety of ADV7103 will be assessed by evaluating the frequency of Treatment-Emergent Adverse events as compared to placebo

    Number/proportion of subjects presenting with ADV7103 treatment-related adverse events (AEs) during the study, by severity grade.

    Time frame: To 30 months

07

Study locations

1 site
  • University of South Florida Pediatric Infectious Diseases
    Tampa, Florida 33606, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jan 2025, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Feb 5, 2019
StartActual
Dec 20, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Mar 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03831152
Lead sponsor
Advicenne Pharma
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Dec 20, 2023
Primary completion
Jan 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Feb 9, 2026

Study contacts

Andre Ulmann, M.D., Ph.D.
study chair · Advicenne Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ADV7103

Start the discussion